Dynavax Technologies Corporation (DVAX): Dynavax Initiates Phase I Trial In … – Seeking Alpha

Dynavax Technologies Corporation (DVAX): Dynavax Initiates Phase I Trial In
Seeking Alpha
After the close of the markets on Wednesday, October 9, 2013, Dynavax (DVAX) announced it will begin dosing patients in the first human trial in its asthma program. The trial, which is being conducted under a collaborative agreement with AstraZeneca

View full post on asthma – Google News

DYNAVAX TECHNOLOGIES CORPORATION : Dynavax Initiates First Human … – 4-traders (press release)

DYNAVAX TECHNOLOGIES CORPORATION : Dynavax Initiates First Human
4-traders (press release)
BERKELEY, CA — (Marketwired) — 10/09/13 — Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the start of dosing in the first human clinical trial in its asthma program. Dynavax is conducting the trial under its collaboration agreement 
Dynavax starts Phase I trial of asthma treatmentSan Francisco Business Times (blog)
Dynavax Initiates First Human Trial in Asthma ProgramMENAFN.COM

all 3 news articles »

View full post on asthma – Google News

Nascent Endothelium Initiates Th2 Polarization of Asthma.

Nascent Endothelium Initiates Th2 Polarization of Asthma.

J Immunol. 2013 Feb 20;

Authors: Asosingh K, Cheng G, Xu W, Savasky BM, Aronica MA, Li X, Erzurum SC

Abstract
Asthma airway remodeling is linked to Th2 inflammation. Angiogenesis is a consistent feature of airway remodeling, but its contribution to pathophysiology remains unclear. We hypothesized that nascent endothelial cells in newly forming vessels are sufficient to initiate Th2-inflammation. Vascular endothelial (VE)-cadherin is a constitutively expressed endothelial cell adhesion molecule that is exposed in its monomer form on endothelial tip cells prior to adherens junction formation. Abs targeted to VE-cadherin monomers inhibit angiogenesis by blocking this adherens junction formation. In this study, VE-cadherin monomer Ab reduced angiogenesis in the lungs of the allergen-induced murine asthma model. Strikingly, Th2 responses including, IgE production, eosinophil infiltration of the airway, subepithelial fibrosis, mucus metaplasia, and airway-hyperreactivity were also attenuated by VE-cadherin blockade, via mechanisms that blunted endothelial IL-25 and proangiogenic progenitor cell thymic stromal lymphopoietin production. The results identify angiogenic responses in the origins of atopic inflammation.

PMID: 23427249 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

GlaxoSmithKline initiates Phase III refractory asthma program – Equities.com

GlaxoSmithKline initiates Phase III refractory asthma program
Equities.com
The Phase III program includes two key studies: MEA115588: A 32-week multicenter, randomized, double-blind, double-dummy, placebo-controlled study in patients with severe uncontrolled refractory asthma. The primary endpoint of the study is to evaluate
Glaxo Starting Late-Stage Study of Asthma DrugPharmaceutical Processing
GlaxoSmithKline starts final-stage tests on severe asthma drugFox News
GSK takes severe asthma antibody into phase IIIPMLiVE
Zenopa –Fox Business –WHTC
all 25 news articles »

View full post on asthma – Google News

KaloBios Initiates Phase 2 Study with KB003 Humaneered™ Monoclonal … – The Herald | HeraldOnline.com

KaloBios Initiates Phase 2 Study with KB003 Humaneered™ Monoclonal
The Herald | HeraldOnline.com
KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered™ monoclonal antibody, in subjects with severe asthma

and more »

View full post on asthma – Google News

Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for … – Sacramento Bee

Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for
Sacramento Bee
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2012 — /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product
Rigel commences R343 and R333 Phase 2 studies in allergic asthma, discoid News-Medical.net
Leerink Swann Starts Rigel Pharmaceuticals (RIGL) at Outperform; Top Biotech StreetInsider.com (subscription)

all 4 news articles »

View full post on asthma – Google News

Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for … – The Herald | HeraldOnline.com

Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for
The Herald | HeraldOnline.com
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2012 — /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product
Rigel Pharma (RIGL) Starts Clinical Studies For Asthma, Discoid LupusiStockAnalyst
Rigel Begins Trial With Advanced Proprietary Therapeutic Product CandidatesNASDAQ

all 13 news articles »

View full post on asthma – Google News

Harvard Clinical Research Institute Initiates Comparative Effectiveness Study … – Business Wire (press release)

Harvard Clinical Research Institute Initiates Comparative Effectiveness Study
Business Wire (press release)
Tiotropium) Study, the purpose of which is to investigate whether Black patients with asthma are more likely to experience adverse outcomes as a result of long-acting beta-agonist (LABA) therapy. The BELT study was funded by a grant from the Agency for

and more »

View full post on asthma – Google News

Harvard Clinical Research Institute Initiates Comparative Effectiveness Study … – Genetic Engineering News

Harvard Clinical Research Institute Initiates Comparative Effectiveness Study
Genetic Engineering News
Tiotropium) Study, the purpose of which is to investigate whether Black patients with asthma are more likely to experience adverse outcomes as a result of long-acting beta-agonist (LABA) therapy. The BELT study was funded by a grant from the Agency for

and more »

View full post on asthma – Google News

Targacept initiates two anti-inflammatory drug studies – Pharmaceutical Business Review

Targacept initiates two anti-inflammatory drug studies
Pharmaceutical Business Review
Targacept has initiated two separate Phase II studies of its product candidate TC-6987 in disorders characterised by inflammation, in asthma and Type II
Targacept to begin Phase 2 trials of drug that could treat asthma, diabetesWinston-Salem Journal
Targacept starts new trial for diabetes drugBizjournals.com
TARGACEPT : Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and 4-traders (press release)

all 18 news articles »

View full post on asthma – Google News